Scarica l'app Stockscreener
35.17
0.80%
0.28
Dopo l'orario di chiusura:
35.17
Precedente Chiudi:
$34.89
Aprire:
$35.01
Volume 24 ore:
1.19M
Relative Volume:
0.59
Capitalizzazione di mercato:
$7.25B
Reddito:
$2.09B
Utile/perdita netta:
$424.88M
Rapporto P/E:
17.21
EPS:
2.0439
Flusso di cassa netto:
$447.20M
1 W Prestazione:
+6.64%
1M Prestazione:
-12.01%
6M Prestazione:
-24.91%
1 anno Prestazione:
-16.90%
Intervallo 1D:
$34.96
$35.43
Intervallo di 1 settimana:
$32.94
$35.43
Portata 52W:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Nome
Qiagen Nv
Settore
Industria
Telefono
-
Indirizzo
-
Compare QGEN vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
35.17 | 7.20B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-06-24 | Iniziato | Barclays | Overweight |
| 2025-04-04 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-10-17 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-06-27 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-07 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-09-12 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-10-14 | Iniziato | Redburn | Buy |
| 2021-07-14 | Downgrade | Kepler | Buy → Hold |
| 2021-06-03 | Iniziato | Goldman | Neutral |
| 2020-10-06 | Ripresa | BofA Securities | Buy |
| 2020-09-28 | Aggiornamento | Kepler | Hold → Buy |
| 2020-08-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-08-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-08-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Downgrade | Berenberg | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-12-26 | Ripresa | BofA/Merrill | Underperform |
| 2019-11-15 | Iniziato | Stifel | Hold |
| 2019-11-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Aggiornamento | Kepler | Reduce → Hold |
| 2019-10-17 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Downgrade | Kepler | Hold → Reduce |
| 2019-10-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Qiagen Nv Borsa (QGEN) Ultime notizie
Qiagen N.V. stock (NL0012169213): Jefferies cuts target as diagnostics group navigates post-pandemic - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): oncology ramp and new diagnostics deals put focus on growth mix - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. stock (NL0012169213): Legal probes and price drop unsettle investors - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics group updates investors after solid Q1 2026 - AD HOC NEWS
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
Qiagen N.V. Stock 12‑Month Price Target Cut to $42.04, Implies 20% Upside - TradingView
Qiagen stock (NL0012169213): Shares rise after Q1 update and guidance reaffirmation - AD HOC NEWS
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform - TradingView
Qiagen N.V. stock (NL0012169213): Outlook raised after Q1 2026 update and new AI assistant launch - AD HOC NEWS
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
QIAGEN Discloses Million-Dollar Insider Share Purchase by Supervisory Board Member Trust - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen launches AI assistant for laboratory research By Investing.com - Investing.com South Africa
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows - BioSpace
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Qiagen stock (NL0012169213): Q1 update and share-price backdrop - AD HOC NEWS
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflo - PharmiWeb.com
Qiagen launches AI assistant for laboratory research - Investing.com
New QIAGEN AI lab assistant is designed to speed experiment planning - Stock Titan
QIAGEN launches AI assistant for laboratory workflow support - StreetInsider
Qiagen N.V. stock (NL0012169213): Diagnostics group lifts 2026 outlook after first?quarter earnings - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): steady earnings backdrop as shares lag 2026 highs - AD HOC NEWS
Qiagen (QGEN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
QIAGEN and NVIDIA partner on AI drug discovery - Yahoo Finance
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA - BioSpace
Qiagen stock (NL0012169213): Q1 update keeps diagnostics and life-science demand in focus - AD HOC NEWS
QIAGEN partners with NVIDIA on AI drug discovery platform By Investing.com - Investing.com Nigeria
QIAGEN partners with NVIDIA on AI drug discovery platform - Investing.com UK
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V. - Business Wire
QIAGEN partners with NVIDIA to integrate AI into drug discovery platform - StreetInsider
Bank of America Discloses 2.98% Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen's Digital Insights Business to Integrate Nvidia's BioNeMo Platform - marketscreener.com
Qiagen discloses AFM notification on 2.99% Bank of America stake - TipRanks
Qiagen N.V. stock (NL0012169213): earnings outlook and molecular diagnostics focus - AD HOC NEWS
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $36 - Moomoo
Citigroup downgrades Qiagen NV (QGEN) - MSN
Qiagen N.V. stock (NL0012169213): diagnostics specialist updates investors after Q1 results - AD HOC NEWS
QGEN Maintained by Stifel -- Price Target Lowered to $36 - GuruFocus
Qiagen stock (NL0012169213): New strategic tie-up puts diagnostics in focus - AD HOC NEWS
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stifel cuts Qiagen stock price target to $36 on weaker outlook By Investing.com - Investing.com Australia
Qiagen stock (NL0012169213): QIAGEN’s U.S. diagnostics exposure stays in focus - AD HOC NEWS
Stifel cuts Qiagen stock price target to $36 on weaker outlook - Investing.com Australia
Qiagen NV (QGEN) PT Lowered to $36 at Stifel on 'Lower Growth Outlook' - StreetInsider
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $36 - Moomoo
Qiagen N.V. (QGEN) Investor Outlook: A 32.87% Upside Potential in the Diagnostics & Research Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Qiagen N.V. (QGEN) And Encourages Investors to Connect - ACCESS Newswire
Qiagen N.V. stock (NL0012169213): earnings momentum and diagnostics demand keep investors watching - AD HOC NEWS
Qiagen Nv Azioni (QGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):